AUTHOR=Leung Daniel , Mu Xiaofeng , Duque Jaime S. Rosa , Cheng Samuel M. S. , Wang Manni , Zhang Wenyue , Zhang Yanmei , Tam Issan Y. S. , Lee Toby S. S. , Lam Jennifer H. Y. , Chan Sau Man , Cheang Cheuk Hei , Chung Yuet , Wong Howard H. W. , Lee Amos M. T. , Li Wing Yan , Chaothai Sara , Tsang Leo C. H. , Chua Gilbert T. , Cheong Kai-Ning , Au Elaine Y. L. , Kwok Janette S. Y. , Chan Koon Wing , Chong Patrick C. Y. , Lee Pamela P. W. , Ho Marco H. K. , Lee Tsz Leung , Tu Wenwei , Peiris Malik , Lau Yu Lung TITLE=Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.982155 DOI=10.3389/fimmu.2022.982155 ISSN=1664-3224 ABSTRACT=

Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.